$13.55
-1.06 (-7.26%)
NVCR News2 articles
NovoCure Jumps 29% on Record Sales, Raised 2026 Guidance
NovoCure shares surged 29% on record Q2 sales and a raised 2026 outlook, with revenue topping consensus by 6.5% and adjusted EBITDA turning positive.
NovoCure Shares Surge on FDA Approval for Pancreatic Cancer Device
NovoCure's stock jumped over 20% premarket after the FDA cleared its Optune Pax device for treating locally advanced pancreatic cancer, marking the first new treatment for this condition in nearly three decades.